-
GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation
GeoVax’s Advanced MVA Manufacturing Platform Supports ASPR-DARPA Vision for Scalable, AI-Integrated Pharmaceutical Production ATLANTA, GA – May 21, 2025 – GeoVax Labs, Inc. (Nasdaq:…
-
GeoVax Reaffirms Urgent Need for Multi-Antigen COVID-19 Vaccines as CDC Shifts Recommendations
GEO-CM04S1 Demonstrates Superior Protection in Immunocompromised Populations; Fully Aligned with HHS Priorities for Durable, Broad-Spectrum Immunization ATLANTA, GA, May 20, 2025 – GeoVax Labs,…
-
GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025
GEO-CM04S1 Demonstrates Robust COVID-19 and Mpox Immunogenicity in Immunocompromised Patients and Healthy Adults ATLANTA, GA, May 8, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX),…
-
GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production
Company’s Advanced Manufacturing Proposal Supports National Biosecurity Goals and Executive Action on Domestic Pharmaceutical Supply Chains ATLANTA, GA, May 6, 2025 – GeoVax Labs,…
-
GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update
OVID-19 vaccine program progressing with additional data evaluating GEO-CM04S1 as booster to mRNA vaccines in healthy adults expected in second quarter of 2025 Clinical…
-
GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting
Advancing Gene-Directed Prodrug Therapy: Data Presented at AACR Supports Gedeptin’s Potential in Solid Tumors ATLANTA, GA, April 29, 2025 – GeoVax Labs, Inc. (Nasdaq:…
-
GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater
GEO-MVA Advancing as the Leading U.S.-Developed Mpox Vaccine Candidate ATLANTA, GA – April 24, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology…
-
GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress
GEO-CM04S1 Demonstrates Durable T Cell and Antibody Responses in Healthy and Immunocompromised Populations ATLANTA, GA, April 24, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX),…
-
GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025
GeoVax to Host Conference Call at 4:30 PM ET Atlanta, GA, April 23, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology…
-
GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations
Recognized Biologics Executive to Oversee Critical Expansion of U.S.-Based Development Capabilities ATLANTA, GA, April 22, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage…
-
GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates
Peer-Reviewed Data Reinforces GeoVax’s Multi-Antigen Strategy with GEO-CM02 and Supports Advancement of GEO-CM04S1 Clinical Programs ATLANTA, GA, April 16, 2025 – GeoVax Labs,…
-
GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum
Company Reaffirms Commitment to Innovation in COVID-19, Oncology, and Biosecurity Amid Strategic Program Developments ATLANTA, GA, April 16, 2025 – GeoVax Labs, Inc. (Nasdaq:…